SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

$MGTA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MGTA alert in real time by email
SC 13G/A 1 d786707dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

 

 

Dianthus Therapeutics, Inc.

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

252828108**

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☑ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

**

The initial filing and Amendment No. 1 were filed on CUSIP 55910K108. Following the completion of the business combination with Dianthus Therapeutics OpCo, Inc. (“OpCo”) in accordance with the terms of the Agreement and Plan of Merger, dated as of May 2, 2023, by and among the Issuer, Dio Merger Sub, Inc. and OpCo, the Common Stock of the Issuer is represented by a new CUSIP number, 252828108.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 252828108    SCHEDULE 13G    Page 2 of 8 Pages

 

 1.   

NAMES OF REPORTING PERSONS

 

Third Rock Ventures IV, L.P.

 2.   

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐  (b) ☑

 

 3.   

SEC USE ONLY

 

 4.   

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

    5.   

SOLE VOTING POWER

 

0

    6.   

SHARED VOTING POWER

 

0

    7.   

SOLE DISPOSITIVE POWER

 

0

    8.   

SHARED DISPOSITIVE POWER

 

0

 9.   

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

10.   

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11.   

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0% (1)

12.   

TYPE OF REPORTING PERSON

 

PN

 

(1)

The percent of class was calculated based on 14,817,762 shares of common stock issued and outstanding as of November 9, 2023, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.


CUSIP No. 252828108    SCHEDULE 13G    Page 3 of 8 Pages

 

 1.   

NAMES OF REPORTING PERSONS

 

Third Rock Ventures GP IV, L.P.

 2.   

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐  (b) ☑

 

 3.   

SEC USE ONLY

 

 4.   

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

    5.   

SOLE VOTING POWER

 

0

    6.   

SHARED VOTING POWER

 

0

    7.   

SOLE DISPOSITIVE POWER

 

0

    8.   

SHARED DISPOSITIVE POWER

 

0

 9.   

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

10.   

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11.   

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0% (1)

12.   

TYPE OF REPORTING PERSON

 

PN


CUSIP No. 252828108    SCHEDULE 13G    Page 4 of 8 Pages

 

 1.   

NAMES OF REPORTING PERSONS

 

TRV GP IV, LLC

 2.   

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐  (b) ☑

 

 3.   

SEC USE ONLY

 

 4.   

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY  

OWNED BY

EACH

REPORTING

PERSON

WITH

    5.   

SOLE VOTING POWER

 

0

    6.   

SHARED VOTING POWER

 

0

    7.   

SOLE DISPOSITIVE POWER

 

0

    8.   

SHARED DISPOSITIVE POWER

 

0

 9.   

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

10.   

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11.   

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0% (1)

12.   

TYPE OF REPORTING PERSON

 

OO


CUSIP No. 252828108    SCHEDULE 13G    Page 5 of 8 Pages

 

Item 1.    Issuer
   (a)    Name of Issuer:
      Dianthus Therapeutics, Inc. (the “Issuer”)
   (b)    Address of Issuer’s Principal Executive Offices:
     

7 Times Square, 43rd Floor

New York, New York, 10036

Item 2.    Filing Person
   (a) –(c)    Name of Persons Filing; Address; Citizenship:
     

(i) Third Rock Ventures IV, L.P. (“TRV IV”);

 

(ii)  Third Rock Ventures GP IV, L.P. (“TRV GP IV”), which is the sole general partner of TRV IV; and

 

(iii)  TRV GP IV, LLC (“TRV GP IV LLC”), which is the sole general partner of TRV GP IV.

 

The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 201 Brookline Ave, Suite 1401, Boston, MA 02215.

 

Each of TRV IV and TRV GP IV is a Delaware limited partnership. TRV GP IV LLC is a Delaware limited liability company.

   (d)    Title of Class of Securities:
      Common stock, $0.001 par value per share, (the “Common Stock”)
   (e)   

CUSIP Number:

 

252828108

Item 3.    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
   (a)       Broker or dealer registered under Section 15 of the Act;
   (b)       Bank as defined in Section 3(a)(6) of the Act;
   (c)       Insurance company as defined in Section 3(a)(19) of the Act;
   (d)       Investment company registered under Section 8 of the Investment Company Act of 1940;
   (e)       An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
   (f)       An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
   (g)       A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
   (h)       A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
   (i)       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
   (j)       A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
   (k)       Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


CUSIP No. 252828108    SCHEDULE 13G    Page 6 of 8 Pages

 

Item 4.

Ownership.

(a) and (b) Amount beneficially owned:

 

(i)

TRV IV directly owns 0 shares of Common Stock (the “Shares”), which represents 0% of the outstanding shares of Common Stock.

 

(ii)

TRV GP IV is the general partner of TRV IV and may be deemed to beneficially own any shares of Common Stock held by TRV IV (if any).

 

(iii)

TRV GP IV LLC is the general partner of TRV GP IV and may be deemed to beneficially own any shares of Common Stock held by TRV IV (if any).

 

(c)

Number of shares as to which such person has:

 

     Number of Shares of Common Stock  
Reporting Person    (i)      (ii)      (iii)      (iv)  

TRV IV

     0        0        0        0  

TRV GP IV

     0        0        0        0  

TRV GP IV LLC

     0        0        0        0  

 

(i)

Sole power to vote or direct the vote

(ii)

Shared power to vote or to direct the vote

(iii)

Sole power to dispose or to direct the disposition of

(iv)

Shared power to dispose or to direct the disposition of

The percent of class was calculated based on 14,817,762 shares of common stock issued and outstanding as of November 9, 2023, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

 

Item  8.

Identification and Classification of Members of the Group.

Not applicable.


CUSIP No. 252828108    SCHEDULE 13G    Page 7 of 8 Pages

 

Item 9.

Notice of Dissolution of Group.

Not applicable.

 

Item 10.

Certification.

Not applicable.


CUSIP No. 252828108    SCHEDULE 13G    Page 8 of 8 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

 

THIRD ROCK VENTURES IV, L.P.
By: THIRD ROCK VENTURES GP IV, L.P.,
General Partner
By: TRV GP IV, LLC,
General Partner
By:   /s/ Kevin Gillis
  Kevin Gillis
  Chief Financial Officer
THIRD ROCK VENTURES GP IV, L.P.
By: TRV GP IV, LLC,
General Partner
By:   /s/ Kevin Gillis
  Kevin Gillis
  Chief Financial Officer
TRV GP IV, LLC
By:   /s/ Kevin Gillis
  Kevin Gillis
  Chief Financial Officer
Get the next $MGTA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MGTA

DatePrice TargetRatingAnalyst
8/25/2022$2.00Buy → Neutral
Goldman
1/24/2022$13.00 → $6.00Buy
B. Riley Securities
1/6/2022$7.00 → $8.00Neutral → Buy
Goldman Sachs
8/20/2021$7.00Neutral
Goldman
8/3/2021$16.00 → $7.00Overweight → Neutral
JP Morgan
7/22/2021$21.00 → $19.00Buy
B. Riley Securities
6/29/2021$20.00Overweight
Cantor Fitzgerald
More analyst ratings

$MGTA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

    CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta") today announced completion of the merger with Dianthus Therapeutics, Inc. ("Dianthus") following Magenta's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta's common stock immediately prior to the merger. Magenta following the merger is referred to herein as the "combined company." Steve Mahoney, President and Chief Financial and Operating Officer of Magenta said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for th

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

    Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus' new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications Companies will host a joint webcast today, May 3, 2023 at 8:30 a.m. ET

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

    CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MGTA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MGTA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MGTA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MGTA
SEC Filings

See more

$MGTA
Leadership Updates

Live Leadership Updates

See more
  • Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

    CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company's R&D Committee and Nominating and Corporate Governance Committee.  "We are delighted to welcome Mike Vasconcelles to the Magenta board," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "Dr. Vasconcelles brings deep experience in research, medical operations, clinical trial design

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

    Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company's Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives. Dr. Humphrey is a medical oncologist with significant leadership experience in drug development and has been involved with the development of more than 20 drug candidates, including regulatory submissions leading to multiple drug approvals in the United States and Europe. "As Magenta continues to advance our clinical and pr

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

    Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first Chief Commercial Officer. "Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "I look forward to working with her in establishing this new functionality as Magenta prepares to enter the next stage of pipeline and product candidate development." As Chief

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MGTA
Financials

Live finance-specific insights

See more
  • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

    CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

    – MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory alignment – – CD45 antibody-drug conjugate (CD45-ADC) IND-enabling studies are advancing – – MGTA-145 clinical trial for stem cell mobilization in sickle cell disease patients is progressing with data now expected to be shared H1 2023 – – Conference call and webcast scheduled for 8:30am ET / 7:30am CT on December 13, 2022 – CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NAS

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

    CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting. The oral presentation at ASH, entitled "MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants

    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MGTA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more